The women's health therapeutics market is booming, with demand for precise, tech-enabled care on the rise. Despite increased pharmaceutical industry involvement, significant gaps in evidence and access persist.
Once a niche area, women's health is now a core growth pillar for pharmaceutical companies. Market forecasts predict the global women's health therapeutics market will reach $66 billion by 2034. A key shift is the move towards therapies tailored to individual genetic profiles and health histories, addressing the historic under-representation of women in clinical trials.
Policy makers are integrating women's health into national strategies. Digital health tools, including apps and wearables, are becoming crucial for tracking symptoms and providing clinicians with richer data. Advanced therapies like biologics and targeted agents are also improving treatment options.
Despite this progress, the market faces challenges from high R&D costs and complex trials. A stark disparity exists, with women and girls receiving only about 6% of health R&D and digital health investment. International Women's Day highlights the need for inclusive research and patient-centered care in women's health.